Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 95
Views pdf: 69
DOI: https://doi.org/10.51298/vmj.v532i1.7237
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Cao, T. T., Vũ, H. T., & Nguyễn, H. H. (2023). EFFICACY AND SAFETY FOR METASTATIC RECURRENCE ESOPHAGEAL CANCER BY DOCETAXEL-CISPLATIN. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7237

EFFICACY AND SAFETY FOR METASTATIC RECURRENCE ESOPHAGEAL CANCER BY DOCETAXEL-CISPLATIN

Thị Thanh Cao1,, Hồng Thăng Vũ1, Hải Hoàng Nguyễn2
1 HMU
2 K Hospital

Main Article Content

Abstract

Purpose: To evaluate the treatment results of a modified administration schedule of Docetaxel- Cisplatin in patients with metastatic esophageal cancer at in the period  of 2018 and 2023. Patients and methods: Descriptive, retrospective study on 55 metastatic recurrence esophageal cancer patients treated with Docetaxel - Cisplatin from june 2018 to june 2023. Results: The response rate was 50.9%, in which the complete response rate was 3.6%, the partial response rate was  47.3%, and the clinical benefit rate was 80%. Median PFS was 5 months. The regimen was well tolerated,  the  most  common side effect  of the  therapy was  neutropenia,  mainly  in grades 2 or 3. Other side effects were mainly encountered in grades 1 or 2. Conclusion: Docetaxel-cisplatin chemotherapy regimen is tolerable and effective for metastatic esophageal cancer patients.

Article Details

Keywords

Metastatic recurrence esophageal cancer, Docetaxel- Cisplatin

References

Hàn Thị Thanh Bình. Nhận xét đặc điểm lâm sàng, mô bệnh học và kết quả điều trị ung thư biểu mô thực quản tại bệnh viện K giai đoạn 1998-2004. Luận án tiến sĩ y học. Đại học y Hà Nội;2004.
2. Chen MQ, Xu BH, Zhang YY. Analysis of prognostic factors for esophageal squamous cell carcinoma with distant organ metastasis at initial diagnosis. J Chin Med Assoc. 2014 Nov;77(11):562–6.
3. Einzig AI, Neuberg Do, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. Med Oncol. 1996 Jun;13(2):87–93.
4. Bang YJ. Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. Jpn J Clin Oncol. 2002 Jul 1;32(7):248–54.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991–7.
6. Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 2010 May;66(1):31–6.
7. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217–23.
8. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, et al. Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660–7.